This presentation took place on Monday, June 17 in Bethesda, MD during the Fifth Annual Biodefense World Summit 2019 and featured Tom Lowery, Ph.D., chief scientific officer, T2 Biosystems. During the presentation, Dr. Lowery highlighted how rapid, direct-from-blood diagnostics – such as the T2Bacteria®, T2Candida®, and T2Resistance™ Panels – can help slow the spread of MDROs and improve patient outcomes. Dr. Lowery also highlighted new data supporting potential future uses of the T2MR® technology for biodefense applications.
During the presentation, Dr. Lowery shared a number of updates on the clinical utility of T2 technology that further prove T2MR’s ability to enable high-sensitivity, blood culture-independent detection of pathogens at an ultra-high sensitivity, including:
New, independent T2Bacteria Panel clinical data demonstrates its ability to substantially benefit patients suspected of sepsis in both the emergency department and intensive care unit by providing information that enables significant reductions in time to effective therapy, de-escalation of unnecessary therapy, and avoidance of premature discharges and readmissions to the emergency department.
Research data shows that the T2Candida auris RUO Panel can detect all four known clades of Candida auris in 5 hours, compared to 14 days with culture methods.
T2Lyme clinical accuracy data show T2Lyme has higher accuracy than any of the currently available methods and a higher positivity rate than existing PCR methods.
New data show that the T2MR technology can detect five biothreat pathogens, including: Bacillus anthracis (anthrax), Burkholderia spp., Rickettsia prowazekii, Francisella tularensis, and Yersinia pestis. These biothreat pathogens can be detected by T2MR technology, which has been proven to work in whole blood (no pre-culture required), environmental samples, other biofluids, and swab samples. The Department of Homeland Security (DHS) has defined these as biothreat pathogens because they require quick antibiotic treatment and can be difficult to diagnose due to non-distinguishing symptoms, making the development and availability of rapid, high-throughput, high sensitivity diagnostics for these biothreat pathogens a national priority.
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, T2Resistance® and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Lyme™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
© 2024 T2 Biosystems, Inc.
Please tell us where you are visiting from: United States | Outside the United States
